.. AVTD freezes its EOS device design for regulatory phase ArtVentive Medical Group, Inc. announced today that the Company offers frozen its Endoluminal Occlusion device style for the peripheral group of indications in preparation for the business’s regulatory phase, ahead of commercialization in European countries and North America and after venturing ahead into Eastern Europe, Japan, Asia Pacific and Latin America. This is another milestone in the Company’s growth and moves the business one step closer to its targeted 2011 European commercialization of the EOS device, said Jim Graham, CEO, ArtVentive Medical Group, Inc. We are pleased with the compounding achievement that we have observed and we anticipate the continued growth of us of EOS devices.The potential of everolimus to advantage patient survival is not yet known.
A gene mixed up in adhesion of cells is less active in breasts tumors with an unhealthy prognosis than the ones that are less aggressive Physicians might be able to produce early decisions on the best treatment for breast cancers, thanks to research published in Breasts Cancer Research today. A gene involved in the adhesion of cells is usually less active in breasts tumors with an unhealthy prognosis than those that are less aggressive, researchers found. Measuring the activity of the ALCAM gene in main breast tumors could give doctors advanced warning about the likely clinical end result of the disease. This will help them decide whether to prescribe a far more aggressive treatment program, such as chemotherapy, much earlier in the diagnostic procedure.